Harvard Stem‑Cell Scandal: 31 Papers Retracted and the Field Shaken

Recently, the academic world faced a major scandal: a Harvard tenured professor was found guilty of academic fraud, resulting in the retraction of 31 papers and the collapse of countless related studies.

Harvard withdrew dozens of papers from top journals, declaring that the entire field of myocardial stem‑cell research was based on fraudulent data. The once‑promising “cardiac stem‑cell therapy” was revealed to be a complete hoax.

According to the New York Times, Harvard retracted the renowned cardiology expert’s research, and RT reported that the expert fabricated 31 studies.

The scandal effectively erased a decade of cardiovascular research that had been built on these false findings. Many scholars, projects, and billions of dollars invested in myocardial stem‑cell research now face uncertainty.

Stem cells can self‑replicate and differentiate, repairing tissues in the body. However, the heart lacks an effective endogenous stem‑cell repair mechanism, making the notion of cardiac stem‑cell regeneration especially appealing.

In 2001, a study claimed that C‑Kit cells injected into damaged hearts could regenerate myocardium, sparking worldwide excitement. The research suggested that bone‑marrow‑derived C‑Kit cells could self‑renew, proliferate, and differentiate into new heart muscle when injected into mice.

The study described a three‑step process: (1) extract stem cells from bone marrow, (2) inject them into the damaged heart, (3) regenerate myocardium. This became the dominant paradigm in cardiac regeneration.

The work was led by Piero Anversa, a Harvard professor celebrated as a leading authority in stem‑cell biology, with dozens of high‑impact publications and hundreds of NIH R01 grants.

Despite the hype, doubts emerged. In 2014, Howard Hughes Medical Institute professor Jeffery Molkentin publicly challenged Anversa’s findings, showing that C‑Kit cells rarely generate new cardiomyocytes in adult mice.

Independent labs attempted to replicate Anversa’s experiments and consistently failed, while Molkentin’s results were reproducible.

Harvard launched an investigation into Anversa’s misconduct, which he resisted, claiming damage to his reputation and financial loss. He left Harvard in 2015, was sued in 2017 for fraud, and the university paid $10 million in damages.

In October 2023, Harvard finally retracted all 31 of Anversa’s papers on cardiac stem cells, stating a commitment to strict academic standards. This marks the most extensive retraction in U.S. history.

The fallout includes wasted billions of research funds, shattered hopes for patients, and a profound impact on the entire field of cardiac regeneration.

Source: 中大科技处